Veru reports strong safety and efficacy for enobosarm added to semaglutide, showing reduced functional decline and muscle ...

The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.

Veru's pivot with enobosarm: groundbreaking Phase 2b results enhance GLP-1 therapy outcomes. A positive launch could yield ...

MIAMI, FL, March 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ ... reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on average lost 71% ...

Veru's Phase 2b study shows enobosarm combined ... receiving semaglutide (Wegovy ) for chronic weight management. Positive Topline Safety Results for the Phase 2b QUALITY Clinical Trial Adverse ...

Veru's enobosarm shows safety when combined with Wegovy, Advanz-Alvotech expand biosimilar deal, Keros gets Glass Lewis support, and GeNeuro receives debt moratorium.

The GLP-1 RA may be either Wegovy® (semaglutide ... to be Available for Phase 3 Clinical Studies and Commercialization Veru is currently developing a novel, patentable, modified release oral ...

Study met primary endpoint: Enobosarm treatment resulted in statistically significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on ...

MIAMI, FL, April 16, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines fo Veru to Present at the 2nd ...